NEOS Investment Management LLC Acquires 22,141 Shares of Edwards Lifesciences Corporation $EW

NEOS Investment Management LLC lifted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 31.9% during the third quarter, HoldingsChannel reports. The firm owned 91,488 shares of the medical research company’s stock after acquiring an additional 22,141 shares during the quarter. NEOS Investment Management LLC’s holdings in Edwards Lifesciences were worth $7,115,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of EW. Rothschild Investment LLC increased its stake in Edwards Lifesciences by 8.1% during the 3rd quarter. Rothschild Investment LLC now owns 14,236 shares of the medical research company’s stock worth $1,107,000 after purchasing an additional 1,065 shares in the last quarter. Merit Financial Group LLC lifted its stake in Edwards Lifesciences by 11.4% in the third quarter. Merit Financial Group LLC now owns 16,459 shares of the medical research company’s stock valued at $1,280,000 after buying an additional 1,683 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after buying an additional 365,581 shares during the period. Tobam increased its position in shares of Edwards Lifesciences by 49.2% during the third quarter. Tobam now owns 67,056 shares of the medical research company’s stock worth $5,215,000 after acquiring an additional 22,124 shares in the last quarter. Finally, Fifth Third Bancorp increased its position in shares of Edwards Lifesciences by 6.0% during the third quarter. Fifth Third Bancorp now owns 25,307 shares of the medical research company’s stock worth $1,968,000 after acquiring an additional 1,437 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 0.7%

Shares of EW opened at $78.97 on Thursday. The firm has a market cap of $45.82 billion, a P/E ratio of 43.15, a price-to-earnings-growth ratio of 2.08 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The firm’s 50-day simple moving average is $82.97 and its 200 day simple moving average is $81.04.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company’s revenue was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Robert W. Baird set a $90.00 price target on Edwards Lifesciences in a report on Monday, January 12th. Truist Financial set a $89.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, February 11th. BTIG Research reiterated a “buy” rating and set a $103.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Evercore reaffirmed an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research report on Monday, January 5th. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $96.14.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. This trade represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This trade represents a 16.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 43,804 shares of company stock worth $3,699,082 in the last 90 days. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.